Advertisement
U.S. markets close in 2 hours 52 minutes

Forza X1, Inc. (FRZA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6210+0.0201 (+3.34%)
As of 12:56PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.6009
Open0.5465
Bid0.6100 x 3000
Ask0.6200 x 1000
Day's Range0.6000 - 0.6470
52 Week Range0.4400 - 3.9800
Volume58,766
Avg. Volume50,580
Market Cap9.789M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FRZA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Forza X1, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more